FDA Approves POMALIDOMIDE — Aurobindo Pharma Limited

# FDA Approves Generic Pomalidomide; Aurobindo Pharma Enters Multiple Myeloma Market Aurobindo Pharma Limited received FDA approval for its generic pomalidomide oral formulation, enabling the Indian pharmaceutical manufacturer to compete in the multiple myeloma treatment segment and potentially capture market share from Celgene's branded Pomalyst. The approval is expected to increase treatment accessibility and drive cost reductions for patients and payers in the immunomodulatory drug category.